Stabilized GHRH analog. FDA-approved for HIV-related visceral adiposity; off-label for body composition.
Trans-3-hexenoyl-stabilized GHRH(1-44). Approved as Egrifta SV for HIV-associated lipodystrophy. RCTs show 11-18% reduction in visceral adipose tissue over 6 months. Off-label use for general body recomposition is widespread; cardiovascular and IGF-1 monitoring recommended.
FDA-approved indication is HIV lipodystrophy. Off-label cosmetic body-recomp use carries IGF-1 elevation; periodic labs prudent. Cost is significant.
Stabilized with a trans-3-hexenoyl group at the N-terminus.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Phase 3 trials showed significant reduction in visceral adipose tissue in HIV-infected adults with lipodystrophy. Effect size led to FDA approval (Egrifta) in 2010. Off-label use for body-recomposition extrapolates from this mechanism without dedicated trials.
Source →B-tier with substantiated human data — "if you're going to take one, either take a Tesa+Ipamorelin blend or just a Tesamorelin." Argues exogenous GH at competitive prices ($200-300/mo) often beats Tesamorelin on cost-per-effect.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 1-2 mg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 1-2 mg daily subcutaneous (off-label body-recomp dose; FDA-approved indication is HIV lipodystrophy at 2 mg)
Egrifta SV brand. Insurance covers HIV-lipodystrophy indication only; off-label use is cash-pay.
As of 2026-04Wide availability at 503A pharmacies with prescription. Order-of-magnitude cheaper than brand for off-label use.
As of 2026-04MX farmacias magistrales prepare Tesamorelin under broader latitude than US 503A.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
Swiss-headquartered global peptide API manufacturer with FDA-registered facilities. Supplies APIs to multiple FDA-approved drug brands.
Multi-region peptide API manufacturer with reactor capacity from 20 L to 28,000 L.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin · Semaglutide · Tirzepatide
Houston-based 503A compounding pharmacy, one of the largest in the US peptide compounding market.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin
FDA approved (Egrifta) — off-label use common
COFEPRIS regulates Mexican farmacias magistrales (compounding pharmacies) under different rules than the US 503A bulks-list framework. Several Mexican compounding pharmacies prepare BPC-157, TB-500, CJC-1295/Ipamorelin, Tesamorelin, and GHK-Cu without the FDA Category 2 ban that has constrained US compounding since 2023.
FDA approved Tesamorelin (Egrifta SV) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The first GHRH analog to receive full US drug approval.